Peter Libby: Exploring Inflammation in Atherosclerosis: Lessons and Therapeutic Implications
Peter Libby, Mallinckrodt Professor of Medicine and Cardiovascular Specialist at Harvard Medical School and Brigham and Womens Hospital, shared a post on LinkedIn:
“Oliver Soehnlein led our update on inflammation in atherosclerosis and the opportunities for novel therapies to quench the smoldering within the plaque and improve clinical outcomes. Table 1 features “Emerging preclinical interference strategies aimed at reducing atherosclerosis” and Figure 5 presents a “Timeline of major milestones of research connecting inflammation with atherosclerosis” which we hope ongoing studies and clinical trials will soon extend as we seek the “sweet spot” of calming inflammation while avoiding undue interference with host defenses or tumor surveillance. Libby and Soehnlein, Inflammation in atherosclerosis: Lessons and therapeutic implications, Immunity (2025),”
Title: Inflammation in atherosclerosis: Lessons and therapeutic implications
Authors: Peter Libby, Oliver Soehnlein
Read full article here.
Stay updated with Hemostasis Today.
-
Oct 9, 2026, 10:40What New U.S. Data Reveal About GT – Glanzmann’s Research Foundation
-
Oct 9, 2026, 10:32Anjali Pandey: The Morphologic Clues to MDS With del(5q)
-
Oct 9, 2026, 10:13Reza Shojaei: 5 Leadership Responsibilities for a Sustainable Plasma Ecosystem
-
Oct 9, 2026, 08:38Johannes Gratz: Perioperative Care in Factor VII Deficiency – Treating the Patient, Not the Number
-
Oct 9, 2026, 08:28Ghanim Fajish: Vascular Cells May Retain a Prothrombotic Memory of Oxidative Stress
-
Oct 9, 2026, 07:43Mehmet Cilingiroglu: The First Diagnosis of Coronary Thrombosis in a Living Patient
-
Oct 9, 2026, 07:21Federico Ravaioli: 40 kPa Spleen Stiffness May Help Avoid Endoscopy in Chronic PVT
-
Oct 9, 2026, 07:00Danny Reardon: Closing the Global Awareness Gap on Blood Clots
-
Oct 9, 2026, 00:54Mary Catherine Moffett: Advancing Advocacy Together – Highlights from the Sanofi Bleeding Disorders Summit